S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
Log in
NASDAQ:ABEO

Abeona Therapeutics Competitors

$2.42
-0.07 (-2.81 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.36
Now: $2.42
$2.87
50-Day Range
$1.76
MA: $2.30
$3.39
52-Week Range
$0.99
Now: $2.42
$3.79
Volume13.99 million shs
Average Volume5.41 million shs
Market Capitalization$238.44 million
P/E RatioN/A
Dividend YieldN/A
Beta1.69

Competitors

Abeona Therapeutics (NASDAQ:ABEO) Vs. CARA, PTGX, PRTA, PAHC, LXRX, and EPIX

Should you be buying ABEO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Abeona Therapeutics, including Cara Therapeutics (CARA), Protagonist Therapeutics (PTGX), Prothena (PRTA), Phibro Animal Health (PAHC), Lexicon Pharmaceuticals (LXRX), and ESSA Pharma (EPIX).

Cara Therapeutics (NASDAQ:CARA) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Volatility & Risk

Cara Therapeutics has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Cara Therapeutics and Abeona Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cara Therapeutics00403.00
Abeona Therapeutics01502.83

Cara Therapeutics currently has a consensus price target of $34.50, indicating a potential upside of 88.01%. Abeona Therapeutics has a consensus price target of $5.1667, indicating a potential upside of 113.50%. Given Abeona Therapeutics' higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Cara Therapeutics.

Earnings & Valuation

This table compares Cara Therapeutics and Abeona Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cara Therapeutics$19.89 million45.97$-106,370,000.00($2.49)-7.37
Abeona Therapeutics$3 million79.48$-76,280,000.00($1.51)-1.60

Abeona Therapeutics has lower revenue, but higher earnings than Cara Therapeutics. Cara Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cara Therapeutics and Abeona Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cara Therapeutics-360.35%-64.36%-53.22%
Abeona TherapeuticsN/A-37.97%-28.76%

Insider and Institutional Ownership

67.0% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 36.5% of Abeona Therapeutics shares are owned by institutional investors. 5.7% of Cara Therapeutics shares are owned by company insiders. Comparatively, 19.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Abeona Therapeutics beats Cara Therapeutics on 10 of the 14 factors compared between the two stocks.

Protagonist Therapeutics (NASDAQ:PTGX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Volatility & Risk

Protagonist Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Protagonist Therapeutics and Abeona Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Protagonist Therapeutics00703.00
Abeona Therapeutics01502.83

Protagonist Therapeutics currently has a consensus price target of $36.25, indicating a potential upside of 53.80%. Abeona Therapeutics has a consensus price target of $5.1667, indicating a potential upside of 113.50%. Given Abeona Therapeutics' higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Protagonist Therapeutics.

Earnings & Valuation

This table compares Protagonist Therapeutics and Abeona Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$230,000.003,920.51$-77,190,000.00($2.98)-7.91
Abeona Therapeutics$3 million79.48$-76,280,000.00($1.51)-1.60

Abeona Therapeutics has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Protagonist Therapeutics and Abeona Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Protagonist Therapeutics-252.03%-54.00%-35.38%
Abeona TherapeuticsN/A-37.97%-28.76%

Insider and Institutional Ownership

97.5% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 36.5% of Abeona Therapeutics shares are owned by institutional investors. 14.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 19.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Abeona Therapeutics beats Protagonist Therapeutics on 10 of the 14 factors compared between the two stocks.

Prothena (NASDAQ:PRTA) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Volatility & Risk

Prothena has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Insider and Institutional Ownership

90.2% of Prothena shares are owned by institutional investors. Comparatively, 36.5% of Abeona Therapeutics shares are owned by institutional investors. 30.4% of Prothena shares are owned by company insiders. Comparatively, 19.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Prothena and Abeona Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prothena00703.00
Abeona Therapeutics01502.83

Prothena currently has a consensus price target of $28.2857, indicating a potential upside of 26.73%. Abeona Therapeutics has a consensus price target of $5.1667, indicating a potential upside of 113.50%. Given Abeona Therapeutics' higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Prothena.

Earnings & Valuation

This table compares Prothena and Abeona Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prothena$810,000.001,100.05$-77,680,000.00($1.95)-11.45
Abeona Therapeutics$3 million79.48$-76,280,000.00($1.51)-1.60

Abeona Therapeutics has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Prothena and Abeona Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prothena-13,615.75%-41.97%-26.26%
Abeona TherapeuticsN/A-37.97%-28.76%

Phibro Animal Health (NASDAQ:PAHC) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Volatility & Risk

Phibro Animal Health has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500.

Insider & Institutional Ownership

50.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 36.5% of Abeona Therapeutics shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 19.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Phibro Animal Health and Abeona Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Phibro Animal Health11102.00
Abeona Therapeutics01502.83

Phibro Animal Health currently has a consensus target price of $21.50, indicating a potential downside of 0.32%. Abeona Therapeutics has a consensus target price of $5.1667, indicating a potential upside of 113.50%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Phibro Animal Health.

Valuation & Earnings

This table compares Phibro Animal Health and Abeona Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phibro Animal Health$800.40 million1.09$33.55 million$1.0819.97
Abeona Therapeutics$3 million79.48$-76,280,000.00($1.51)-1.60

Phibro Animal Health has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Phibro Animal Health and Abeona Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Phibro Animal Health5.37%23.70%5.99%
Abeona TherapeuticsN/A-37.97%-28.76%

Summary

Phibro Animal Health beats Abeona Therapeutics on 9 of the 14 factors compared between the two stocks.

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Volatility & Risk

Lexicon Pharmaceuticals has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500.

Insider & Institutional Ownership

84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 36.5% of Abeona Therapeutics shares are owned by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 19.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Lexicon Pharmaceuticals and Abeona Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexicon Pharmaceuticals06202.25
Abeona Therapeutics01502.83

Lexicon Pharmaceuticals currently has a consensus target price of $9.40, indicating a potential upside of 30.74%. Abeona Therapeutics has a consensus target price of $5.1667, indicating a potential upside of 113.50%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Lexicon Pharmaceuticals.

Valuation & Earnings

This table compares Lexicon Pharmaceuticals and Abeona Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexicon Pharmaceuticals$322.07 million2.71$130.13 million$1.355.33
Abeona Therapeutics$3 million79.48$-76,280,000.00($1.51)-1.60

Lexicon Pharmaceuticals has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lexicon Pharmaceuticals and Abeona Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%
Abeona TherapeuticsN/A-37.97%-28.76%

Summary

Abeona Therapeutics beats Lexicon Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

ESSA Pharma (NASDAQ:EPIX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Volatility & Risk

ESSA Pharma has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500.

Insider & Institutional Ownership

63.4% of ESSA Pharma shares are owned by institutional investors. Comparatively, 36.5% of Abeona Therapeutics shares are owned by institutional investors. 19.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for ESSA Pharma and Abeona Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ESSA Pharma00403.00
Abeona Therapeutics01502.83

ESSA Pharma currently has a consensus target price of $23.50, indicating a potential downside of 13.25%. Abeona Therapeutics has a consensus target price of $5.1667, indicating a potential upside of 113.50%. Given Abeona Therapeutics' higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than ESSA Pharma.

Valuation & Earnings

This table compares ESSA Pharma and Abeona Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ESSA PharmaN/AN/A$-23,440,000.00($1.04)-26.05
Abeona Therapeutics$3 million79.48$-76,280,000.00($1.51)-1.60

ESSA Pharma has higher earnings, but lower revenue than Abeona Therapeutics. ESSA Pharma is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ESSA Pharma and Abeona Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ESSA PharmaN/A-46.31%-45.08%
Abeona TherapeuticsN/A-37.97%-28.76%

Summary

Abeona Therapeutics beats ESSA Pharma on 7 of the 12 factors compared between the two stocks.


Abeona Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cara Therapeutics logo
CARA
Cara Therapeutics
1.8$18.35-5.0%$914.42 million$19.89 million-8.66Earnings Announcement
Insider Selling
News Coverage
Gap Down
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$23.57-1.8%$901.72 million$230,000.00-10.96News Coverage
Gap Down
Prothena logo
PRTA
Prothena
2.1$22.32-1.3%$891.04 million$810,000.00-8.72Analyst Upgrade
Insider Buying
Gap Down
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$21.57-3.3%$872.57 million$800.40 million20.35High Trading Volume
Gap Up
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.8$7.19-4.0%$871.31 million$322.07 million-6.85News Coverage
ESSA Pharma logo
EPIX
ESSA Pharma
1.1$27.09-6.1%$868.61 millionN/A-25.08Analyst Report
Increase in Short Interest
News Coverage
Gap Up
Radius Health logo
RDUS
Radius Health
1.3$18.61-2.3%$866.24 million$173.32 million-7.63Earnings Announcement
Analyst Report
News Coverage
Gap Down
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.5$22.23-3.8%$845.59 million$14.87 million-8.29News Coverage
Gap Down
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$22.10-1.2%$840.82 millionN/A-7.62Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$18.47-4.7%$839.41 millionN/A0.00Upcoming Earnings
Gap Down
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.53-2.1%$832.75 million$322.36 million125.21High Trading Volume
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.59-10.3%$815.79 million$296.70 million48.14Earnings Announcement
Analyst Downgrade
News Coverage
Gap Down
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$3.37-2.7%$815.72 million$2.22 million-19.82Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Odonate Therapeutics logo
ODT
Odonate Therapeutics
2.1$21.05-3.1%$812.61 millionN/A-5.37Earnings Announcement
Analyst Revision
News Coverage
Gap Up
Kadmon logo
KDMN
Kadmon
2.0$4.59-0.2%$787.25 million$5.09 million-7.65Upcoming Earnings
News Coverage
AnaptysBio logo
ANAB
AnaptysBio
1.1$28.70-9.5%$784.89 million$8 million-10.59Earnings Announcement
Insider Buying
Analyst Revision
News Coverage
Gap Up
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.39-1.1%$763.55 million$148.36 million-7.11Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Provention Bio logo
PRVB
Provention Bio
1.4$12.72-0.9%$718.53 millionN/A-8.54Earnings Announcement
Analyst Report
News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$21.66-6.4%$714.61 million$252 million-2.21Earnings Announcement
Analyst Downgrade
High Trading Volume
Analyst Revision
News Coverage
Gap Down
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$9.40-4.1%$713.72 millionN/A-2.64Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Merus logo
MRUS
Merus
1.4$22.50-8.9%$711.07 million$31.13 million-7.33Gap Up
OrganiGram logo
OGI
OrganiGram
1.2$3.03-1.7%$703.78 million$64.61 million-4.46Unusual Options Activity
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$4.15-0.2%$701.27 million$59.29 million-27.66Upcoming Earnings
Analyst Report
News Coverage
Gap Down
Akouos logo
AKUS
Akouos
1.7$20.37-2.1%$700.38 millionN/A0.00Upcoming Earnings
High Trading Volume
News Coverage
Gap Down
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.6$16.54-1.7%$697.29 million$17.26 million-4.59
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$28.07-2.7%$672.81 million$19.56 million-20.19Analyst Report
Decrease in Short Interest
News Coverage
Gap Down
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$34.86-0.6%$665.02 million$9.64 million-5.68Earnings Announcement
Analyst Revision
News Coverage
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.4$18.68-3.0%$653.93 million$6.83 million-19.26Upcoming Earnings
Analyst Report
BCEL
Atreca
1.7$17.35-2.3%$636.87 millionN/A-6.15Earnings Announcement
News Coverage
Gap Down
Chimerix logo
CMRX
Chimerix
1.3$9.81-8.8%$614.44 million$12.52 million-17.21Earnings Announcement
News Coverage
Gap Down
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$32.87-1.1%$589.75 million$12.69 million-15.80Analyst Report
Insider Selling
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$16.46-1.0%$589.50 millionN/A0.00Upcoming Earnings
Ardelyx logo
ARDX
Ardelyx
1.9$6.45-0.3%$582.10 million$5.28 million-6.39Upcoming Earnings
News Coverage
Gap Down
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.5$44.50-2.9%$579.84 million$195.89 million127.15Upcoming Earnings
Gap Down
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$12.17-12.2%$577.71 millionN/A-4.89Upcoming Earnings
Gap Down
IVA
Inventiva
0.0$15.00-3.6%$575.90 millionN/A0.00Gap Down
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$6.77-3.0%$559.03 million$56.50 million0.00Decrease in Short Interest
Gap Down
XBiotech logo
XBIT
XBiotech
1.2$19.00-0.3%$555.96 millionN/A1.32News Coverage
Geron logo
GERN
Geron
1.4$1.79-1.1%$555.75 million$460,000.00-5.11
IDYA
IDEAYA Biosciences
1.3$19.07-4.7%$554.37 millionN/A-10.14Gap Up
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$21.72-5.6%$553.73 millionN/A-4.56Insider Buying
News Coverage
Gap Down
IVERIC bio logo
ISEE
IVERIC bio
1.5$6.14-2.1%$549.95 millionN/A-4.87Upcoming Earnings
News Coverage
Molecular Templates logo
MTEM
Molecular Templates
2.0$10.90-1.1%$544.61 million$22.27 million-5.34Analyst Upgrade
Insider Buying
News Coverage
Gap Down
AC Immune logo
ACIU
AC Immune
1.3$7.59-0.9%$544.51 million$111.75 million-8.43
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$11.02-0.5%$543.45 million$72.96 million-3.57
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$33.34-1.5%$541.51 millionN/A-15.44Gap Down
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$25.27-1.3%$538.38 million$13.80 million-12.21
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.17-0.1%$529.45 millionN/A-3.14
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.99-0.8%$529.03 million$143.01 million-1.14Earnings Announcement
Analyst Report
Analyst Revision
Altimmune logo
ALT
Altimmune
1.9$15.94-7.9%$527.15 million$5.80 million-8.01Earnings Announcement
Analyst Revision
News Coverage
Gap Down
This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.